Modulation of endogenous AICAR levels for the treatment of diabetes and obesity
    1.
    发明申请
    Modulation of endogenous AICAR levels for the treatment of diabetes and obesity 审中-公开
    调节内源性AICAR水平治疗糖尿病和肥胖

    公开(公告)号:US20070015720A1

    公开(公告)日:2007-01-18

    申请号:US11347811

    申请日:2006-02-03

    IPC分类号: A61K31/7056

    摘要: The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle, pancreatic beta or certain brain cells) increases AICAR-monophosphate levels which in turn results in activation of the AMP-kinase (AMPK) pathway, and all of the downstream functions mediated by AMPK including increased fatty acid oxidation, enhanced glucose transport and decreased fatty acid synthesis.

    摘要翻译: 本发明涉及通过施用增加细胞内源性AICAR-MP水平的AICAR-一磷酸(AICAR-MP)增强剂治疗2型糖尿病,肥胖症,代谢综合征和与此相关的病症的方法。 在调节代谢活性的细胞(如脂肪,肝脏,肌肉,胰腺β或某些脑细胞)中抑制AICAR-甲酰转移酶活性(AICARFT)增加AICAR-单磷酸盐水平,这反过来导致AMP-激酶(AMPK )途径,并且由AMPK介导的所有下游功能包括增加的脂肪酸氧化,增强的葡萄糖转运和降低的脂肪酸合成。